Log in

ProShares UltraPro NASDAQ Biotechnology Stock Price, News & Analysis (NASDAQ:UBIO)

$22.22
+0.93 (+4.37 %)
(As of 10/23/2019 08:27 AM ET)
Add
Today's Range
$22.22
Now: $22.22
$23.36
50-Day Range
$17.54
MA: $20.36
$22.66
52-Week Range
$15.76
Now: $22.22
$33.19
Volume92,088 shs
Average Volume43,900 shs
Market Capitalization$25.55 million
P/E RatioN/A
Dividend Yield0.00%
BetaN/A

Basic Details

Issuer ProShares
Fund NameProShares UltraPro NASDAQ Biotechnology
Tax ClassificationRegulated Investment Company
SymbolNASDAQ:UBIO
Inception Date6/22/2015
Fund ManagerMichael Neches, Tarak Dave
WebN/A
PhoneN/A

Fund Focus

Asset ClassEquity
BenchmarkNASDAQ Biotechnology Index
CategorySector
FocusHealth Care
Development LevelDeveloped Markets
RegionNorth America

Fund Statistics

Assets Under Management$27.77 million
Average Daily Volume$32,536.00
Discount/Premium-0.03%

ETF Expenses

Management Fee0.75%
Other Expenses0.57%
Total Expenses1.32%
Fee Waiver-0.37%
Net Expenses0.95%

Administrator, Advisor and Custodian

AdministratorJ.P. Morgan Investor Services Co.
AdvisorProShare Advisors LLC
CustodianJPMorgan Chase Bank, N.A.
DistributorSEI Investments Distribution Co.
Transfer AgentJPMorgan Chase Bank, N.A.
Trustee
Lead Market MakerVirtu Financial

Receive UBIO News and Ratings via Email

Sign-up to receive the latest news and ratings for UBIO and its competitors with MarketBeat's FREE daily newsletter.


Geographic Exposure of ProShares UltraPro NASDAQ Biotechnology (NASDAQ:UBIO)
Currency Exposure of ProShares UltraPro NASDAQ Biotechnology (NASDAQ:UBIO)
Sector Exposure of ProShares UltraPro NASDAQ Biotechnology (NASDAQ:UBIO)
Industry Exposure of ProShares UltraPro NASDAQ Biotechnology (NASDAQ:UBIO)

ProShares UltraPro NASDAQ Biotechnology (NASDAQ:UBIO) Frequently Asked Questions

What is ProShares UltraPro NASDAQ Biotechnology's stock symbol?

ProShares UltraPro NASDAQ Biotechnology trades on the NASDAQ under the ticker symbol "UBIO."

Has ProShares UltraPro NASDAQ Biotechnology been receiving favorable news coverage?

Media coverage about UBIO stock has trended negative recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. ProShares UltraPro NASDAQ Biotechnology earned a media sentiment score of -2.5 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the immediate future. View News Stories for ProShares UltraPro NASDAQ Biotechnology.

What other stocks do shareholders of ProShares UltraPro NASDAQ Biotechnology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ProShares UltraPro NASDAQ Biotechnology investors own include Energous (WATT), Amarantus Bioscience (AMBS), WisdomTree Japan Hedged SmallCap Equity Fund (DXJS), Universal Display (OLED), Progenics Pharmaceuticals (PGNX), Asante Solutions (PUMP), Qiwi (QIWI), Regeneron Pharmaceuticals (REGN), Retrophin (RTRX) and Sunrun (RUN).

How do I buy shares of ProShares UltraPro NASDAQ Biotechnology?

Shares of UBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is ProShares UltraPro NASDAQ Biotechnology's stock price today?

One share of UBIO stock can currently be purchased for approximately $22.22.

How big of a company is ProShares UltraPro NASDAQ Biotechnology?

ProShares UltraPro NASDAQ Biotechnology has a market capitalization of $25.55 million. View Additional Information About ProShares UltraPro NASDAQ Biotechnology.


MarketBeat Community Rating for ProShares UltraPro NASDAQ Biotechnology (NASDAQ UBIO)

Community Ranking:  1.8 out of 5 (star)
Outperform Votes:  52 (Vote Outperform)
Underperform Votes:  89 (Vote Underperform)
Total Votes:  141
MarketBeat's community ratings are surveys of what our community members think about ProShares UltraPro NASDAQ Biotechnology and other stocks. Vote "Outperform" if you believe UBIO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe UBIO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/23/2019 by MarketBeat.com Staff

Featured Article: Technical Analysis

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel